The therapeutic potential of targeting tryptophan catabolism in cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The therapeutic potential of targeting tryptophan catabolism in cancer
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 122, Issue 1, Pages 30-44
Publisher
Springer Science and Business Media LLC
Online
2019-12-10
DOI
10.1038/s41416-019-0664-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
- (2019) Geoffrey T. Gibney et al. Journal for ImmunoTherapy of Cancer
- Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
- (2019) Michael Platten et al. NATURE REVIEWS DRUG DISCOVERY
- Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
- (2019) Kyung Hae Jung et al. CLINICAL CANCER RESEARCH
- A novel dual inhibitor of IDO and TDO, CMG017, potently suppresses the kynurenine pathway and overcomes resistance to immune checkpoint inhibitors.
- (2019) Chan Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39
- (2019) Maisa C. Takenaka et al. NATURE NEUROSCIENCE
- IDO1 maintains pluripotency of primed human embryonic stem cells by promoting glycolysis
- (2019) Xin Liu et al. STEM CELLS
- Increase Paclitaxel Sensitivity to Better Suppress Serous Epithelial Ovarian Cancer via Ablating Androgen Receptor/Aryl Hydrocarbon Receptor-ABCG2 Axis
- (2019) Wei-Min Chung et al. Cancers
- Serine-Glycine-One-Carbon Metabolism: The Hidden Achilles Heel of MYCN-Amplified Neuroblastoma?
- (2019) Aida Rodriguez Garcia et al. CANCER RESEARCH
- Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas
- (2019) Shuyu Hao et al. JOURNAL OF NEURO-ONCOLOGY
- Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice
- (2019) Timothy Affolter et al. PLoS One
- Kynurenine signaling through the aryl hydrocarbon receptor maintains the undifferentiated state of human embryonic stem cells
- (2019) Takako Yamamoto et al. Science Signaling
- Aryl hydrocarbon receptor counteracts pharmacological efficacy of doxorubicin via enhanced AKR1C3 expression in triple negative breast cancer cells
- (2019) Naoya Yamashita et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- MYC promotes tryptophan uptake and metabolism by the kynurenine pathway in colon cancer
- (2019) Niranjan Venkateswaran et al. GENES & DEVELOPMENT
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
- (2019) Georgina V Long et al. LANCET ONCOLOGY
- Evaluation of integrin αvβ6 cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis
- (2019) Richard H. Kimura et al. Nature Communications
- Development of a mass spectrometry-based tryptophan 2, 3-dioxygenase assay using liver cytosol from multiple species
- (2018) Jing Wang et al. ANALYTICAL BIOCHEMISTRY
- Expression profile of the amino acid transporters SLC7A5, SLC7A7, SLC7A8 and the enzyme TDO2 in basal cell carcinoma
- (2018) E Tina et al. BRITISH JOURNAL OF DERMATOLOGY
- Tumor-Repopulating Cells Induce PD-1 Expression in CD8 + T Cells by Transferring Kynurenine and AhR Activation
- (2018) Yuying Liu et al. CANCER CELL
- A patent review of IDO1 inhibitors for cancer
- (2018) Jae Eun Cheong et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- HOXC10 promotes proliferation and invasion and induces immunosuppressive gene expression in glioma
- (2018) Shu Li et al. FEBS Journal
- Regulation of the Immune Response by the Aryl Hydrocarbon Receptor
- (2018) Cristina Gutiérrez-Vázquez et al. IMMUNITY
- Reversal of indoleamine 2,3-dioxygenase–mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme
- (2018) Todd A Triplett et al. NATURE BIOTECHNOLOGY
- The T-win® technology: immune-modulating vaccines
- (2018) Mads Hald Andersen Seminars in Immunopathology
- Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities
- (2018) Jae Eun Cheong et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas
- (2018) Maud Toulmonde et al. JAMA Oncology
- Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
- (2018) Asha Nayak-Kapoor et al. Journal for ImmunoTherapy of Cancer
- Human AML activates the AHR pathway to impair NK cell development and function
- (2018) Steven D. Scoville et al. BLOOD
- The roles of the COX2/PGE2/EP axis in therapeutic resistance
- (2018) Dali Tong et al. CANCER AND METASTASIS REVIEWS
- Expression of the IDO1/TDO2–AhR pathway in tumor cells or the tumor microenvironment is associated with MCPyV status and prognosis in Merkel cell carcinoma
- (2018) Lusi Oka Wardhani et al. HUMAN PATHOLOGY
- Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
- (2018) Tara C. Mitchell et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human study of KHK2455, a long-acting, potent and selective indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor, in combination with mogamulizumab (Moga), an anti-CCR4 monoclonal antibody, in patients (pts) with advanced solid tumors.
- (2018) Timothy Anthony Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- A Role for Tryptophan-2,3-dioxygenase in CD8 T Cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma
- (2018) Lisa I Greene et al. MOLECULAR CANCER RESEARCH
- Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
- (2018) Bruno Gomes et al. MOLECULAR CANCER THERAPEUTICS
- TDO2 Overexpression Is Associated with Cancer Stem Cells and Poor Prognosis in Esophageal Squamous Cell Carcinoma
- (2018) Quoc Thang Pham et al. ONCOLOGY
- Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML)
- (2018) Melanie Gentil et al. PLoS One
- Durable Clinical Responses and Long-Term Follow-Up of Stage III–IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study—A Brief Research Report
- (2018) Julie Westerlin Kjeldsen et al. Frontiers in Immunology
- Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer
- (2018) Eric Fox et al. Frontiers in Oncology
- Exploring the transcriptome of hormone-naive multifocal prostate cancer and matched lymph node metastases
- (2018) Linnéa Schmidt et al. BRITISH JOURNAL OF CANCER
- Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase
- (2018) Maria Winters et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Current state on tryptophan 2,3-dioxygenase inhibitors: a patent review
- (2018) Arina Kozlova et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Invasion and migration of MDA-MB-231 cells are inhibited by block of AhR and NFAT: role of AhR/NFAT1/β4 integrin signaling
- (2018) Amir Shadboorestan et al. JOURNAL OF APPLIED TOXICOLOGY
- Cyclooxygenase-2 in cancer: A review
- (2018) Nasser Hashemi Goradel et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma
- (2018) Sébastien Corre et al. Nature Communications
- The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
- (2017) Lieve Brochez et al. EUROPEAN JOURNAL OF CANCER
- Epigenetic Strategies to Boost Cancer Immunotherapies
- (2017) Maria Barrero INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate
- (2017) Stefano Crosignani et al. JOURNAL OF MEDICINAL CHEMISTRY
- Chromatographic analysis of tryptophan metabolites
- (2017) Ilona Sadok et al. JOURNAL OF SEPARATION SCIENCE
- Pre-Interventional Kynurenine Predicts Medium-Term Outcome after Contrast Media Exposure Due to Coronary Angiography
- (2017) Christoph Reichetzeder et al. KIDNEY & BLOOD PRESSURE RESEARCH
- ATIM-29. A PHASE 1 STUDY OF PF-06840003, AN ORAL INDOLE 2,3-DIOXYGENASE 1 (IDO1) INHIBITOR IN PATIENTS WITH MALIGNANT GLIOMAS
- (2017) David Reardon et al. NEURO-ONCOLOGY
- Preparation and evaluation of L- and D-5-[ 18 F]fluorotryptophan as PET imaging probes for indoleamine and tryptophan 2,3-dioxygenases
- (2017) Tang Tang et al. NUCLEAR MEDICINE AND BIOLOGY
- Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors activate the aryl hydrocarbon receptor
- (2017) Benjamin J. Moyer et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Synthesis of 5-[18F]Fluoro-α-methyl Tryptophan: New Trp Based PET Agents
- (2017) Benjamin C. Giglio et al. Theranostics
- Strong Correlation of Indoleamine 2,3-Dioxygenase 1 Expression with Basal-Like Phenotype and Increased Lymphocytic Infiltration in Triple-Negative Breast Cancer
- (2017) Sewha Kim et al. Journal of Cancer
- Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance
- (2017) Marc Hennequart et al. Cancer Immunology Research
- Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer
- (2017) Dyah L. Dewi et al. OncoImmunology
- Biological and clinical significance of tryptophan-catabolizing enzymes in cutaneous T-cell lymphomas
- (2017) Pilvi Maliniemi et al. OncoImmunology
- Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis
- (2017) Wouter Hendrickx et al. OncoImmunology
- Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer
- (2017) Daniel E. Carvajal-Hausdorf et al. Journal for ImmunoTherapy of Cancer
- Tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase 1 make separate, tissue-specific contributions to basal and inflammation-induced kynurenine pathway metabolism in mice
- (2016) Paul B. Larkin et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- 1,2,3-Triazoles as inhibitors of indoleamine 2,3-dioxygenase 2 (IDO2)
- (2016) Ute F. Röhrig et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Analysis of Kynurenine/Tryptophan ratio and expression of IDO1 and 2 mRNA in tumour tissue of cervical cancer patients
- (2016) Jayakumar Hascitha et al. CLINICAL BIOCHEMISTRY
- Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies
- (2016) A. M. Monjazeb et al. CLINICAL CANCER RESEARCH
- The end of the road for the tryptophan depletion concept in pregnancy and infection
- (2016) A. A.- B. Badawy et al. CLINICAL SCIENCE
- Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab
- (2016) Jon Bjoern et al. CYTOTHERAPY
- Prognostic value of indoleamine 2,3-dioxygenase activity and expression in nasopharyngeal carcinoma
- (2016) Ahlem Ben-Haj-Ayed et al. IMMUNOLOGY LETTERS
- Tolerogenic Phenotype of IFN-γ–Induced IDO+Dendritic Cells Is Maintained via an Autocrine IDO–Kynurenine/AhR–IDO Loop
- (2016) Qingsheng Li et al. JOURNAL OF IMMUNOLOGY
- Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4
- (2016) Katharina Ochs et al. JOURNAL OF NEUROCHEMISTRY
- General control non-derepressible 2 (GCN2) in T cells controls disease progression of autoimmune neuroinflammation
- (2016) Melanie Keil et al. JOURNAL OF NEUROIMMUNOLOGY
- Assessment of Tryptophan Uptake and Kinetics Using 1-(2- 18 F-Fluoroethyl)-l-Tryptophan and α- 11 C-Methyl-l-Tryptophan PET Imaging in Mice Implanted with Patient-Derived Brain Tumor Xenografts
- (2016) Sharon K. Michelhaugh et al. JOURNAL OF NUCLEAR MEDICINE
- Improved Radiosynthesis and Biological Evaluations of L- and D-1-[18F]Fluoroethyl-Tryptophan for PET Imaging of IDO-Mediated Kynurenine Pathway of Tryptophan Metabolism
- (2016) Yangchun Xin et al. MOLECULAR IMAGING AND BIOLOGY
- Fully automated radiosynthesis of N1-[18F]fluoroethyl-tryptophan and study of its biological activity as a new potential substrate for indoleamine 2,3-dioxygenase PET imaging
- (2016) Jean Henrottin et al. NUCLEAR MEDICINE AND BIOLOGY
- IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
- (2016) David H. Munn et al. TRENDS IN IMMUNOLOGY
- Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment
- (2016) Cara C. Schafer et al. Oncotarget
- Stress Kinase GCN2 Controls the Proliferative Fitness and Trafficking of Cytotoxic T Cells Independent of Environmental Amino Acid Sensing
- (2016) Lee-Ann Van de Velde et al. Cell Reports
- The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas
- (2016) Jana K. Sonner et al. OncoImmunology
- Tryptophan PET Imaging of the Kynurenine Pathway in Patient-Derived Xenograft Models of Glioblastoma
- (2016) Anthony R. Guastella et al. Molecular Imaging
- IDO1 is an Integral Mediator of Inflammatory Neovascularization
- (2016) Arpita Mondal et al. EBioMedicine
- The Role of Indoleamine 2,3-Dioxygenase in Diethylnitrosamine-Induced Liver Carcinogenesis
- (2016) Yuhei Shibata et al. PLoS One
- A TDO2-AhR Signaling Axis Facilitates Anoikis Resistance and Metastasis in Triple-Negative Breast Cancer
- (2015) Nicholas C. D'Amato et al. CANCER RESEARCH
- Inhibition of indoleamine 2,3-dioxygenase 1 expression alters immune response in colon tumor microenvironment in mice
- (2015) Manabu Takamatsu et al. CANCER SCIENCE
- Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers
- (2015) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- The amino acid sensor GCN2 inhibits inflammatory responses to apoptotic cells promoting tolerance and suppressing systemic autoimmunity
- (2015) Buvana Ravishankar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The breakdown of the anelastic approximation in rotating compressible convection: implications for astrophysical systems
- (2015) M. A. Calkins et al. PROCEEDINGS OF THE ROYAL SOCIETY A-MATHEMATICAL PHYSICAL AND ENGINEERING SCIENCES
- NAD+ in aging, metabolism, and neurodegeneration
- (2015) E. Verdin SCIENCE
- Differential Regulation of Th17 and T Regulatory Cell Differentiation by Aryl Hydrocarbon Receptor Dependent Xenobiotic Response Element Dependent and Independent Pathways
- (2015) Sonia Mohinta et al. TOXICOLOGICAL SCIENCES
- N1-Fluoroalkyltryptophan Analogues: Synthesis and in vitro Study as Potential Substrates for Indoleamine 2,3-Dioxygenase
- (2015) Jean Henrottin et al. ACS Medicinal Chemistry Letters
- Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
- (2015) Rikke B. Holmgaard et al. Cell Reports
- Tumoral Immune Resistance Mediated by Enzymes That Degrade Tryptophan
- (2015) N. van Baren et al. Cancer Immunology Research
- Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer
- (2015) Mads Duus Hjortsø et al. OncoImmunology
- Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance
- (2015) Nathalie Vigneron et al. OncoImmunology
- Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers
- (2015) Tara C Gangadhar et al. Journal for ImmunoTherapy of Cancer
- Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR
- (2015) Ulrike M. Litzenburger et al. Oncotarget
- A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors
- (2015) Hatem H. Soliman et al. Oncotarget
- The Aryl Hydrocarbon Receptor: Multitasking in the Immune System
- (2014) Brigitta Stockinger et al. Annual Review of Immunology
- Inhibition of De Novo NAD + Synthesis by Oncogenic URI Causes Liver Tumorigenesis through DNA Damage
- (2014) Krishna S. Tummala et al. CANCER CELL
- Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway
- (2014) Martina Ott et al. GLIA
- IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation
- (2014) Richard Metz et al. INTERNATIONAL IMMUNOLOGY
- The SOCS3-Independent Expression of IDO2 Supports the Homeostatic Generation of T Regulatory Cells by Human Dendritic Cells
- (2014) S. Trabanelli et al. JOURNAL OF IMMUNOLOGY
- Identification of Cinnabarinic Acid as a Novel Endogenous Aryl Hydrocarbon Receptor Ligand That Drives IL-22 Production
- (2014) Margaret M. Lowe et al. PLoS One
- Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
- (2014) I. Theate et al. Cancer Immunology Research
- IDO2 in Immunomodulation and Autoimmune Disease
- (2014) George C. Prendergast et al. Frontiers in Immunology
- The Role of Placental Tryptophan Catabolism
- (2014) Peter Sedlmayr et al. Frontiers in Immunology
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
- (2014) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- GCN2 kinase plays an important role triggering the remission phase of experimental autoimmune encephalomyelitis (EAE) in mice
- (2013) Heloisa Orsini et al. BRAIN BEHAVIOR AND IMMUNITY
- Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase
- (2013) T. Z. Iversen et al. CLINICAL CANCER RESEARCH
- Aryl hydrocarbon receptor signaling regulates NF-κB RelB activation during dendritic-cell differentiation
- (2013) Christoph F A Vogel et al. IMMUNOLOGY AND CELL BIOLOGY
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer
- (2013) J. Yu et al. JOURNAL OF IMMUNOLOGY
- Up-regulated expression of indoleamine 2,3-dioxygenase 1 in non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltration
- (2013) Xiao-Qian Liu et al. LEUKEMIA & LYMPHOMA
- The Cancer Genome Atlas Pan-Cancer analysis project
- (2013) John N Weinstein et al. NATURE GENETICS
- The Genotype-Tissue Expression (GTEx) project
- (2013) John Lonsdale et al. NATURE GENETICS
- Expression of Tryptophan 2,3-Dioxygenase and Production of Kynurenine Pathway Metabolites in Triple Transgenic Mice and Human Alzheimer's Disease Brain
- (2013) Wei Wu et al. PLoS One
- Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer
- (2013) Ben C. Creelan et al. OncoImmunology
- Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase
- (2012) Mee Young Chang et al. CANCER BIOLOGY & THERAPY
- Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of human T cell proliferation
- (2012) Feng Qian et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immunological and Nonimmunological Effects of Indoleamine 2,3-Dioxygenase on Breast Tumor Growth and Spontaneous Metastasis Formation
- (2012) Vera Levina et al. Clinical & Developmental Immunology
- Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
- (2012) L. Pilotte et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development
- (2012) Courtney Smith et al. Cancer Discovery
- IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan
- (2012) Richard Metz et al. OncoImmunology
- Spontaneous Cytotoxic T-Cell Reactivity against Indoleamine 2,3-Dioxygenase-2
- (2011) R. B. Sorensen et al. CANCER RESEARCH
- Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival
- (2011) Jonathan R. Brody et al. CELL CYCLE
- High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma
- (2011) Jocelyne Jacquemier et al. INTERNATIONAL JOURNAL OF CANCER
- Tryptophan 2,3-Dioxygenase (TDO) Inhibitors. 3-(2-(Pyridyl)ethenyl)indoles as Potential Anticancer Immunomodulators
- (2011) Eduard Dolušić et al. JOURNAL OF MEDICINAL CHEMISTRY
- Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase
- (2011) R Meisel et al. LEUKEMIA
- An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
- (2011) Christiane A. Opitz et al. NATURE
- Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
- (2010) X. Liu et al. BLOOD
- Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators
- (2010) R. B. Sorensen et al. BLOOD
- The aryl hydrocarbon receptor (AhR) in the regulation of cell-cell contact and tumor growth
- (2010) C. Dietrich et al. CARCINOGENESIS
- An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
- (2010) J. D. Mezrich et al. JOURNAL OF IMMUNOLOGY
- Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism
- (2010) N. T. Nguyen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis
- (2010) F. J. Quintana et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Aryl Hydrocarbon Receptor Antagonists Promote the Expansion of Human Hematopoietic Stem Cells
- (2010) Anthony E. Boitano et al. SCIENCE
- CH223191 Is a Ligand-Selective Antagonist of the Ah (Dioxin) Receptor
- (2010) Bin Zhao et al. TOXICOLOGICAL SCIENCES
- Kynurenic Acid Is a Potent Endogenous Aryl Hydrocarbon Receptor Ligand that Synergistically Induces Interleukin-6 in the Presence of Inflammatory Signaling
- (2010) Brett C. DiNatale et al. TOXICOLOGICAL SCIENCES
- Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma
- (2009) Tomoko Inaba et al. GYNECOLOGIC ONCOLOGY
- Tryptophan Deprivation Induces Inhibitory Receptors ILT3 and ILT4 on Dendritic Cells Favoring the Induction of Human CD4+CD25+ Foxp3+ T Regulatory Cells
- (2009) M. Brenk et al. JOURNAL OF IMMUNOLOGY
- Genotyping and Expression Analysis of IDO2 in Human Pancreatic Cancer: A Novel, Active Target
- (2009) Agnieszka K. Witkiewicz et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase
- (2009) Rikke Bæk Sørensen et al. PLoS One
- Infectious tolerance via the consumption of essential amino acids and mTOR signaling
- (2009) S. P. Cobbold et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Toll-Like Receptor Engagement Enhances the Immunosuppressive Properties of Human Bone Marrow-Derived Mesenchymal Stem Cells by Inducing Indoleamine-2,3-dioxygenase-1 via Interferon-β and Protein Kinase R
- (2009) Christiane A. Opitz et al. STEM CELLS
- Mouse Mesenchymal Stem Cells Suppress Antigen-Specific TH Cell Immunity Independent of Indoleamine 2,3-Dioxygenase 1 (IDO1)
- (2009) Tobias V. Lanz et al. STEM CELLS AND DEVELOPMENT
- Tryptophan 2,3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice
- (2009) Masaaki Kanai et al. Molecular Brain
- Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase
- (2008) Christoph F.A. Vogel et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism
- (2008) Stefan Löb et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Inverse Correlation between Tumoral Indoleamine 2,3-Dioxygenase Expression and Tumor-Infiltrating Lymphocytes in Endometrial Cancer: Its Association with Disease Progression and Survival
- (2008) K. Ino et al. CLINICAL CANCER RESEARCH
- Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma
- (2008) Ke Pan et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Expression of Indoleamine 2,3-Dioxygenase in Metastatic Pancreatic Ductal Adenocarcinoma Recruits Regulatory T Cells to Avoid Immune Detection
- (2008) Agnes Witkiewicz et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Immune escape as a fundamental trait of cancer: focus on IDO
- (2008) G C Prendergast ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now